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Specific T-cell activation
in an unspecific T-cell repertoire
HUGO A. VAN DEN BERG, CARMEN MOLINA-PARÍS, ANDREW K.
SEWELL
ABSTRACT
T-cells are a vital type of white blood cell that circulate around our bodies, scan-
ning for cellular abnormalities and infections. They recognise disease-associated
antigens via a surface receptor called the T-cell antigen receptor (TCR). If there
were a specific TCR for every single antigen, no mammal could possibly contain all
the T-cells it needs. This is clearly absurd and suggests that T-cell recognition must,
to the contrary, be highly degenerate. Yet highly promiscuous TCRs would appear
to be equally impossible: they are bound to recognise self as well as non-self anti-
gens. We review how contributions from mathematical analysis have helped to
resolve the paradox of the promiscuous TCR. Combined experimental and theo-
retical work shows that TCR degeneracy is essentially dynamical in nature, and
that the T-cell can differentially adjust its functional sensitivity to the salient epi-
tope, “tuning up” sensitivity to the antigen associated with disease and “tuning
down” sensitivity to antigens associated with healthy conditions. This paradigm of
continual modulation affords the TCR repertoire, despite its limited numerical di-
versity, the flexibility to respond to almost any antigenic challenge while avoiding
autoimmunity.
Keywords: T-cell activation, T-cell antigen receptor, mathematical modelling,
TCR repertoire, co-receptor, costimulation
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1 Introduction
T-cells are a type of white blood cell that circulate around our bodies, scanning for
cellular abnormalities and infections (Figure 1). Without T-cells, human immunity
does not function optimally1. For instance, in AIDS, one particular type of T-cell
is present in lower than normal numbers and the devastating effects are all too
well-known. Almost every aspect of the adaptive immune response is controlled,
in some way, by T-cells. It is important to understand how T-cells are regulated,
not only to enhance the beneficial responses, but also to suppress unwanted actions
of T-cells. The latter include rejection of a transplanted organ, virtually all autoim-
mune disease (diabetes, multiple sclerosis, rheumatoid arthritis), as well as certain
allergic reactions, such as gluten intolerance1.
There are several different kinds of T-cell. They can be divided into two dif-
ferent types, called killer T-cells and helper T-cells. The latter are the ones that
fail in AIDS. T-cells have a way of telling what is happening inside our bodies’
own cells simply by scanning their surface. This mechanism allows killer T-cells
to hunt down and destroy cells that are infected with germs or that have become
cancerous1. Closely related to the killer T-cells that mediate this immune response
are memory cells, which remain in the system, so that it can remember a pathogen
that was encountered years or even decades ago2,3.
1.1 How T-cells work
T-cells recognise molecular markers of disease, called antigens, via a surface re-
ceptor known as the T-cell antigen receptor (TCR). TCR recognition of antigens
takes place in the contact area between a T cell and an antigen-presenting cell
(APC)4. TCR molecules bind to ligands on the surface of the APC, as shown in
Figure 2. Each ligand molecule consists of a peptide (a protein fragment) attached
to a specialized antigen-presenting receptor encoded by the major histocompati-
bility complex (MHC) of genes. The peptides are generated by cutting up pro-
teins into small fragments5. As the size of these peptide fragments increases, the
probability that a nonself (pathogen-derived) peptide also occurs in the human self
decreases6.
Upon binding to a peptide/MHC (pMHC) molecule, transmembrane molecules
associated with the TCR acquire the ability to transmit signals to the cellular in-
terior by phosphorylation of intracellular signalling domains associated with the
TCR/CD3 complex7. This process of TCR triggering leads to various cellular re-
sponses, such as changes in gene expression or the killing of a target cell1.
The pMHC ligands found on a single APC form a mixed population of thou-
sands of different species5,8. Most of these are ‘harmless’, that is, derived from
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host proteins not associated with disease, or from non-pathogenic organisms.
T cell efficacy rests on the ability to respond to ‘harmful’, that is, disease-
associated, antigens while remaining non-responsive to the harmless background
against which these ‘harmful’ ligands are presented. A key problem in immunol-
ogy is to understand precisely how the immune system achieves such discrimina-
tion. This problem is known as the self-nonself problem, a misleading misnomer
since self-derived ligands may be associated with disease, while the body harbours
many nonself proteomes which are perfectly harmless and are normally ignored by
the immune system9.
Before they become activated, T-cells reside in the lymphoid tissues as qui-
escent cells. This is the TCR repertoire. It is created by random mutation and
contains about a million different TCR clonotypes10.
1.2 The controversial idea of a promiscuous TCR repertoire
We have discovered that a lack of specificity is a hallmark of the T-cell antigen
receptor repertoire. This might seem a startling, if not foolhardy, claim in view of
the undeniable fact any given TCR clonotype is capable of engaging productively
with only a minute subset of all possible pMHC species. The favoured ligands for
a given TCR are said to be the agonists of that TCR. Since T-cells must avoid re-
sponding to antigens not associated with harm (such as autoantigens), an intuitively
obvious starting point is the assumption that TCR recognitions is one-to-one, that
is, there is a specific TCR for each antigen. However, if this were the case, the
repertoire would struggle for adequate coverage of the space of possible epitopes.
Mason11 pointed out that there cannot possibly be a single TCR for each antigen,
since this would require an immune system vastly larger than the host organism
(Figure 3). This led him to the conclusion that T-cell recognition must be highly
degenerate, whatever perplexities this might entail. In other words, the minute
subset is nonetheless very large, possibly containing many thousands of strong ag-
onists12,13.
The concept of a highly promiscuous TCR is controversial and has met with
skepsis that continues until the present day—assuaged at least partly by the accu-
mulating evidence for tuning mechanisms, which allow the T cell to modulate its
antigen sensitivity by adjusting the expression of surface molecules and intracellu-
lar signalling machinery14–20. Mathematical modelling of the TCR/peptide-MHC
interaction has shown just how powerful these modulatory mechanisms are, and
has led to a new concept of dynamic differential regulation of functional sensi-
tivity. Here, we give an overview of the main ideas in non-technical language;
references to mathematical publications are given below and in Van den Berg and
Rand 21 . We shall concentrate mainly on our own efforts since the focus is on our
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controversial claim of TCR promiscuity; a more complete survey of the work of
several theoretical groups has been published elsewhere22, and the reader is urged
to consult this reference for further key citations to the field.
2 TCR degeneracy
The time-honoured “lock-and-key” model might be taken to suggest that the TCR
key either fits the pMHC lock, or fails to fit. In reality, the strength of recognition
lies on a continuous scale. This is well known from experiments in which antigen-
presenting cells (APCs) are incubated with various doses of the agonist, and an
EC50 is determined. Taking the logarithm of the reciprocal of this EC50, one ob-
tains the pEC50 which can be viewed as a quality parameter: strong recognition
is characterised by a high pEC50, whereas a low pEC50 indicates weak recogni-
tion. The name functional avidity has become entrenched in the literature (as in
“high-avidity” versus “low-avidity” clones sensu Alexander-Miller 23 ), but given
the other meanings of this term, we prefer functional sensitivity.
2.1 Functional sensitivity and degeneracy
The riddle of the promiscuous TCR starts to dissolve when one comes to terms
with the idea that degeneracy is in essence a statistical concept. In particular, TCR
degeneracy is defined completely and precisely by the statistical distribution of a
given TCR’s functional sensitivity values for all possible pMHC epitopes. TCR
degeneracy is not a number, but a curve, as illustrated in Figure 4. This curve is a
quantification of the idea that for a fixed TCR, there are few very strong agonists,
perhaps scores of moderate agonists, and hundreds to thousands of weak agonists.
The degeneracy distribution can be experimentally determined and can also be
calculated from the underlying statistics on kinetic parameters24, exploiting the re-
lation between kinetics and functional sensitivity which is explained in more detail
in Box 1. The T-cell can modulate the shape of this distribution curve (Figure 4).
Thus, under some circumstances, a T-cell may behave very much as predicted by
the classic lock-and-key concept, with a distribution that concentrates its probabil-
ity mass at the very end points of the functional sensitivity range, whereas under
other circumstances, the T-cell can have a range of moderate functional sensitiv-
ities (implying that the T-cell response can be modulated to be narrow or broad
spectrum, or anything in between25).
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2.2 Dynamics of TCR degeneracy modulation
The mechanisms through which the T-cell modulates its degeneracy are complex.
There are two threshold levels: the triggering threshold which is a property of the
individual TCR/CD3 complex, and the cellular activation threshold which is the
property of the whole T-cell, and which expresses the rate and/or number of TCRs
which need to be triggered to elicit a T-cell response (Figure 5). A T-cell may be
capable of various responses, and each of these will have its own threshold value,
giving rise to a response hierarchy26,27. We have recently succeeded in estimating
these cellular thresholds in experiments where various types of cellular responses
were measured as a function of antigen presentation levels.
Both types of thresholds are modulated by changing expression levels of CD45
isoforms, adhesion molecules, CD2, CD28/CD152 and CD4 or CD8 co-receptors,
kinases and phosphorylases28–30. Details of the mathematical analysis are given
by Van den Berg and Sewell31; here we highlight two novel findings.
2.2.1 Dual-receptor signalling in costimulation
The first finding concerns the modulation of the cellular activation threshold. This
threshold is modulated by signals carried by the receptors CD28 and CD125, but
with opposite effects (the former positive, the latter negative; Figure 6). It has been
observed that both CD28 and CD125 can interact with both CD80 and CD86 on
the APC32–34. This cross-talk allows the APC to influence the activation thresh-
old of the T-cell, but only if the T-cell expresses a suitable mixture of CD28 and
CD125. This is an example of a cell-to-cell signalling system where the recipient
determines how it decodes the incoming signal. We have proposed that this effect
is exploited by the immune system to control the oligo/polyclonality of a T-cell
response, as well as the range of functional sensitivity values in the response31.
2.2.2 TCRs tuning in on particular antigens
The second result concerns modulation by the co-receptor CD8. A combination of
experimental and modelling studies18,35,36 indicates that CD8 is not only involved
in controlling degeneracy, but also in differential regulation of functional sensitiv-
ity. This means that the T-cell can increase its functional sensitivity for one ligand
while simultaneously reducing the sensitivity for all others; this concept goes be-
yond the notion that the coreceptor generally up or downregulates the sensitivity
of the TCR17,37. By varying the CD8 expression level, as well as CD8 isoforms,
the T-cell can “tune in”: i.e., select a sensitive epitope from among a wider group
of potential agonists. This gives the T-cell repertoire a degree of flexibility which
alleviates the paradox of TCR promiscuity38.
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3 Genesis of the TCR repertoire
The dynamic picture of TCR degeneracy prompts a radical rethink of the role of
the selection processes in the thymus39. If avoidance of inappropriate selectivity
is achieved through continual modulation of individual T-cells’ sensitivity in the
mature repertoire, where does this leave the thymic selection processes, which are
generally assumed to fulfil this function?
3.1 Enforcement of MHC restriction
It is generally held that negative selection serves to eliminate self-reactive TCR
clonotypes40. One way of being too self-reactive is violating MHC restriction. If
a thymocyte recognizes two or more of the host’s MHC isoforms, it will receive
elevated stimulation by autoantigens. This enhanced self background signal may
give rise to spurious activation (autoimmunity). The importance of allorecognition
as a clinical phenomenon shows that TCRs are commonly capable of engaging
multiple MHC isoforms, implying that safeguarding this restriction with respect to
the autoisoforms must be a major function of negative selection in the thymus.
An important operating parameter of the immune system is the signal/noise ra-
tio between the autoantigen background and the pathogen-derived signal41. Notwith-
standing its degeneracy, a TCR is highly unlikely to have high functional sensitivity
to more than one of the pathogen-derived antigens displayed by the APC, and thus
most of the relevant epitopes will tend to spoil the signal/noise ratio. This ad-
verse effect is counteracted by the presence of highly selective steps in the MHC
presentation pathway. This is the essence of the “diversity filter” theory of MHC
presentation; a more detailed argument hinges on Large Deviations Theory42. A
drawback of the filter is that any given isoform has a non-negligible probability of
presenting no signal at all. The immune system compensates for this by having
several TCR repertoires in parallel, kept separated by their restrictedness to MHC
isoforms which is enforced by negative selection.
3.2 The target of negative selection: not merely autorecognition
One major function of negative selection is to enforce MHC restriction. Apart from
this, would there be an additional need to eliminate autorecognition, given the bat-
tery of modulation mechanisms which will operate on the mature T-cell? After all,
a naïve T-cell, experiencing normal self stimulation in a non-alarm context, could
simply be instructed to increase these thresholds, or differentiate into a regulator-
type cell39,43. This suggests that the function of negative selection is not to elimi-
nate autorecognition per se, but to eliminate the wrong kind of autorecognition—
7
the kind that could easily evade control by the peripheral tuning mechanisms.
Is there such a wrong kind of autorecognition, specifically targetted by negative
selection? Whereas some immunologists believe so44, this has yet to become the
consensus theory1. However, regardless of the merits of either point of view, the
theorists can make an important contribution to the debate: viz., that it is possible to
characterise, in an objective way, the “kind of autorecognition” that this targetted
by negative selection. In particular, it can be shown that the target of negative
selection is encoded unambiguously in the presentation patterns of autoantigens in
the thymus45.
Important statistics that define the target of negative selection are (i) how often
an autoantigen is presented on a negatively-selecting cell, and (ii) its presentation
level, i.e. the MHC copy number at which it occurs when presented. These pre-
sentation statistics determine together the functional sensitivity distribution among
the naïve T-cells in the mature TCR repertoire, as illustrated in Figure 7: the
thymic presentation level determines the truncation point of the degeneracy curves,
whereas the frequency of presentation determines the sharpness of the truncation46.
The statistical structure of functional sensitivity in the TCR repertoire as a
whole is determined by the thymic presentation statistics of all self antigens. The
general theory is quite involved, but we can illustrate it by considering two ex-
amples of particular interest. The first is the case where the thymic presentation
statistics are a truthful reflection of those in the peripheral lymphoid tissues. This
thymic microcosms corresponds most closely to the classical scenario, in that most
likely to be deleted are those thymocytes that would go on to register the most
autorecognition as naïve T-cells. On the second scenario, thymic presentation is
biased towards those autoantigens which occur only in one or a few locations in
the body, but at very high levels where they do. We would then have “thymic se-
lection for tunability,” where most likely to be deleted are those thymocytes which,
as naïve T-cells, could not be reliably down-modulated to avert autoimmunity. The
survivors are those that can adjust their cellular activation threshold dynamically47.
On the latter scenario, central (thymic) and peripheral (tuning) anti-autoimmune
mechanisms serve distinct, complementary functions.
4 Maintaining T-cell repertoire diversity
The functional efficiency of the naïve T-cell repertoire depends on a number of fac-
tors. One is how rapidly a response, once expanded, is able to clear a pathogenic
challenge. Another is how reliably an appropriate clone (one whose TCR has high
functional sensitivity to one of the pathogen’s epitopes) can be identified and ex-
panded within a critical time frame following an pathogenic challenge. Intuitively
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we expect this reliability to be correlated with the clonal diversity in the TCR reper-
toire. Ecologists use a diversity measure called Simpson’s diversity index48. This
is a dimensionless number which equals 1 when all clones are present with equal
numbers of cells, and which equals 0 when one clonotype numerically dominates
all others in terms of T-cells belonging to that type. The typical size of an antigen-
inexperienced clone is almost certainly less than several thousand cells (in hu-
mans), in sharp contrast to expanded antigen-experienced clones which may have
millions of cells each.
Whereas the link between this diversity index and reliability is intuitively plain,
a more careful mathematical treatment invokes the Moderate Deviations Theo-
rem49, which says that, as the Simpson’s diversity index becomes large, the time
required to activate any TCR clone becomes vanishingly unlikely to be substan-
tially longer than the average waiting time across the TCR repertoire50.
4.1 Stochastic dynamics of clone sizes
The next step is to understand how sensitively the diversity (which can be deter-
mined experimentally, in principle) depends on the various random influences that
drive the size of any given clone up or down. A convenient quantity is the co-
efficient of variation (CV, i.e. the mean scaled by the standard deviation) of the
distribution of clonal sizes in the naïve repertoire. Keeping track of millions of
clones poses a formidable computational task. Fortunately, an idea known as the
Ergodic Hypothesis51 brings succour. In the present context, this idea essentially
means that a series of snapshots over time of the cell numbers of any given clone
gives the same general impression as a snapshot at a given moment of time of all
the clones taken together.
Using this ergodicity trick, we can estimate the required CV-value from the
corresponding statistic of a single clone. To obtain this value, we treat the clone as
a stochastic birth-and-death process. This is quite realistic, more so in fact than the
deterministic treatment which has been more commonly followed in mathematical
immunology. The number of cells of the clone is then represented as a continuous-
time Markov chain (Figure 8). The stationary distribution of this Markov chain
expresses, roughly speaking, how much time a typical clone spends at any given
size. Ergodicity then allows us to apply the CV of this stationary Markov chain
distribution to the entire naïve repertoire, and thus calculate its diversity from the
parameters of the Markov chain50,52,53.
A technical difficulty is that the individual clone-related Markov chains do not
actually have a stationary distribution, because every clone must eventually go ex-
tinct. Fortunately, there is a theory which shows that each doomed clone will never-
theless spend most of its limited lifetime following the so-called Quasi-Stationary
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Distribution (QSD; e.g. van Doorn 54 ), and the ergodicity trick still goes through
when we use the QSD to furnish the coefficient of variation, as explained in Box 2.
4.2 Self stimulation and survival
Naïve T-cells are thought to receive survival stimuli that are dependent on the de-
gree to which their TCRs are able to engage autoantigens on a specialized class of
APCs55,56. This hypothesis is attractive since it indicates, at least on an intuitive
level, a means for the repertoire to maximize functional diversity: clones would
be favoured to the extent that their TCR has a recognition profile unlike that of
most other clones. However, the hypothesis raises two questions. The first is how
a huge number of clones can subsist on a much more modest number of autoanti-
gens. The second is how diversity can be protected since the ecological metaphor
of autoantigens as niches suggests that a system is prone to take-over by the most
promiscuous, versatile TCRs through a general mechanism called competitive ex-
clusion48. These two problems are best addressed together since the answers are
closely related.
We start from the assumptions that a TCR recognises multiple autoantigens (at
relatively low functional sensitivity) and that a minimum number of these must be
present in the APC’s autoantigen presentation profile (APP) if the T-cell is going to
receive a survival stimulus from the APC. Applying combinatorics we find an enor-
mous richness of distinct clonotypes (compared to the —possibly quite small— set
of participating autoantigens) as well as a very dilute mode of competition, as is ex-
plained in more detail in Box 3. A T-cell will compete for access to survival stimuli
with almost all other clones, but for any particular APP, it will be competing with
a very small subset of competitors. Moreover, the clone will find itself competing
with a different group of clones for each of the APPs that can potentially furnish a
survival stimulus. As a result, the impact of any one clone on the others is negligi-
ble, which means that competitive exclusion is, perhaps surprisingly, not a major
factor. We see rather that a clone’s chances of survival depend on a quantity called
the mean niche overlap which expresses the expected number of competing clones
for any given APP. Thus, while a clone typically competes with millions of other
clones, for any given APP it only competes with a limited number of clones—in
fact, just one or none at all, in the case of a typical clone: detailed calculations
have shown that a clone with an expected niche overlap greater than 1 has a dra-
matically shortened life time in the repertoire. Again, this one (if any) competitor
will generally be a different clone for each different APP, which is why any given
clone competes only vanishingly weakly with any other clone, unless their TCRs
are very similar. The selection for low average niche overlap favours TCRs with
different recognition signatures. At the same time, the sharp cut-off near unity
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overlap promotes diversity.
5 Perspectives
Mathematical immunology as a discipline is only justified if mathematicians can
provide immunologists with a theoretical support that affords deeper insights, rig-
orous quantification, as well as experimentally testable hypotheses. We have tried
to argue the case by exhibiting various instances where such modelling leads to new
immunological ideas or experiments. Working together as mathematical modellers
and as experimentalists, we have shown that TCR recognition is a graded phe-
nomenon, expressible as functional sensitivity (pEC50). A clone’s degeneracy is
exactly characterised by its functional sensitivity distribution. The fact that T-cells
can modulate this degeneracy using costimulatory receptors and TCR-coreceptors
suggests numerous interesting new experiments as well as immune system-based
therapies. The analysis indicates that T-cells are capable of differential regulation
of functional sensitivity—the key to the paradox of TCR promiscuity.
In the life sciences, the interface of traditional modelling, statistical analysis,
and bioinformatics is now the purview of “systems biologists,” a vogue driven
by an awareness that mathematics is no longer avoidable in analysis (as well as
planning) of large-scale, high-throughput experiments that generate huge amounts
of data.57 No doubt this interface is crucial to immunology as well; hence systems
immunology. We envisage that it will become feasible to determine the functional
specificity of many TCR clonotypes for huge numbers of different peptide ligands;
that it will become possible to follow the clonal sizes of naive clones over the
course of weeks, months, and years; that we will be able to chart the changes of the
functional specificity of a given TCR clone for a given ligand during the course of
its clonal expansion and response, and simultaneously follow the expression levels
of co-receptors and costimulatory receptors. To extract meaning from such data,
and to be able to formulate sensible clinical interventions, systems immunologists
will require the tools provided by our integrative theory.
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Figure 1: T-cells. Left: a T-cell in a petri dish, seen from above. Right: a T-cell
(small cell at the bottom) killing a tumour cell (large cell).
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Figure 2: Antigen presentation and the T-cell. The antigen-presenting cell ac-
quires proteins derived from the pathogen, cuts them into small fragments called
peptides, and presents these on its outer surface on MHC molecules; these interact
with the T-cell antigen receptor located on the outer surface of the T-cell.
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~106 peptides
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Figure 3: The TCR repertoire must cover a vast epitope space. The numbers
indicate the approximate orders of magnitude.
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Figure 4: The T cell can modulate the degeneracy of its TCR. Each curve rep-
resents the number of ligands with functional sensitivity at least as great as the
value on the x-axis, for a fixed T-cell. Functional sensitivity is expressed here
as the difference between the pEC50 of the ligand and that of the optimal ligand;
thus less negative corresponds to a more avid ligand, 0 being the optimum. Thus,
as x increases, fewer and fewer ligands have functional specificities greater than
or equal to x, which is why the curves are monotone decreasing. Differences
between the curves reflect different expression levels of the co-receptor and ki-
nases/phosphorylases in the T-cell:APC contact area. It is apparent that the T-cell
can modulate its degeneracy to a very large degree. Reading off the curves at the
value −0.5, we see that the expected number of pMHC ligands whose functional
sensitivity is within half a decade of the optimum can vary from less than 1 to
several thousands.
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Figure 5: The dual threshold model of T cell activation. Individual TCRs are
triggered by pMHC ligands; collectively they stimulate downstream activation. In
this way, the signals from the TCRs are summed and the sum serves as input into
a decision function at the cellular level; modulating the sum is “signal 2” arising
from costimulation.
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Figure 6: Costimulation. The APC can encode information (for instance, about
copy numbers of salient pMHC on its surface) in its expression levels of two re-
ceptors (CD80 and CD86). Likewise, the T-cell can determine how it decodes this
information by varying the expression levels of two receptors (CD152 and CD28).
The signals from CD152 and CD28 are combined to determine the strength of “sig-
nal 2”, the costimulation required by naive T-cells in addition to TCR triggering.
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Figure 7: The functional sensitivity of self-recognition is determined by thymic
presentation statistics. Each curve represents the number of TCR clonotypes with
functional sensitivity at least as great as the value on the x-axis for a fixed self
peptide (note how this differs from the previous figure). Left panel: numbers of
reactive T-cells are much reduced at high functional specificities, and more strongly
so as the presentation levels on negatively-selecting cells in the thymus increase
(the top curve corresponds to the absence of selection). Right panel: the truncation
is sharper when more negatively-selecting cells present the autoantigen.
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…Figure 8: Stochastic dynamics of a T-cell clone. Solid arrows correspond to cell
division events, open arrows to cell deaths.
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Box 1: Functional sensitivity and TCR/pMHC kinetics
The functional sensitivity of a pMHC ligand can be represented by the following
formula:
x = log
e1−t
tc + t
where t is the average duration of the TCR/pMHC interaction relative to the TCR
triggering threshold and tc is a parameter which depends on the density of free
TCRs on the T-cell surface (see Van den Berg et al. 58 for a full derivation). The
graph shows functional sensitivity x as a function of mean scaled residence time t
for various values of tc. At high surface densities of free TCR molecules (tc  1)
the curve has an optimum at t = 1 (this is the point where the half-life of the
TCR/pMHC interaction equals the receptor triggering threshold time, multiplied
by log 2). This optimum behaviour reflects the serial triggering effect, which
becomes less limiting at low surface densities of free TCR molecules (tc  1);
accordingly, the optimum becomes less pronounced. This means that when the
MHC density is not limiting, the serial triggering effect disappears and ligands
with long interaction times become potent agonists.
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Box 1: Functional sensitivity and TCR/pMHC kinetics
The functional sensitivity of a pMHC ligand can be represented by the following
formula:
x = log
e1−t
tc + t
where t is the average duration of the TCR/pMHC interaction relative to the TCR
triggering threshold and tc is a parameter which depends on the density of free
TCRs on the T cell surface (see Van den Berg et al. (2002) for a full derivation).
The graph shows functional sensitivity x as a function of mean scaled residence
time t for various values of tc. At high surface densities of free TCR molecules
(tc ! 1) the curve has an optimum at t = 1 (this is the point where the half-
life of the TCR/pMHC interaction equals the receptor triggering threshold time,
multiplied by log 2). This optimum behaviour reflects the serial triggering effect,
which becomes less limiting at low surface densities of free TCR molecules (tc "
1); accordingly, the optimum becomes less pronounced. This means that when
the MHC density is not limiting, the serial triggering effect disappears and ligands
with long interaction times become potent agonists.
Note: graphics to appear inside the box
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Box 2: Birth and death model of the number of T-cells of a
particular clone
The number of T-cells of a particular clonotype is modelled as a type of Markov
process called a birth and death process59. The birth rate from a state with n cells
is given by λn and the death rate from a state with n cells is given by µn. This is
illustrated in the following diagram:
0 ↽
µ1
1
λ1

µ2
2
λ2

µ3
3 · · ·n− 1 λn−1

µn
n
λn

µn+1
n+ 1 · · ·
There can be no births or deaths from a state with zero cells so λ0 = µ0 = 0. We
say that zero is an absorbing state; once this state is reached, the T-cell clonotype
becomes extinct. If the birth and death rates satisfy the condition
+∞∑
n=1
µ1µ2 . . . µn
λ1λ2 . . . λn
= +∞
the process is guaranteed to reach the zero state eventually. We have shown that
in our case this condition is satisfied for all values of the parameters. The mean
time to extinction from an initial state with n cells can be computed from the birth
and death rates and is always finite.
We denote by pn(t) the probability that there are n cells at time t. Since extinction
is certain, eventually we have limt→+∞ p0(t) = 1. Therefore, it is useful to
introduce the conditional probability, qn(t), which is the probability that there
are n cells at time t, given that extinction has not yet occurred. Formally, this is
defined as
qn(t) =
pn(t)
1− p0(t) n ≥ 1 .
The limit of this probability distribution as time goes to infinity is called the
quasi-stationary probability distribution (QSD) of the process, and is denoted by
q¯n. The mean and variance of this distribution are given by
n¯ =
+∞∑
n=1
n q¯n and σ2 =
+∞∑
n=1
n2 q¯n − n¯2 ,
respectively. Simpson’s diversity index for the T-cell repertoire can be computed
in terms of these two quantities as follows
DS =
1
1 + (σ/n)2
.
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Box 3: Combinatorics creates an abundance of “niches”
with a limited set of autoantigens
The number of different antigen presentation profiles can be very large, even if the
number of self-peptides that provide survival signals to naïve T-cells is relatively
small. We denote the number of self-peptides which provide survival signals to
the naïve repertoire by NA and the number of self-peptides presented on a single
APP by NAPP, with NA ≥ NAPP. Then to form an APP, NAPP of the NA self-
peptides are chosen and therefore, the number of distinct APPs is given by(
NA
NAPP
)
=
NA!
NAPP!(NA −NAPP)! .
For example, if NA = 1000 and NAPP = 100, the number of distinct APPs is
approximately 6× 10139.
Combinatorics can also be used to calculate the probability that a T-cell of a
given clonotype will receive a survival signal from an APP chosen at random.
This probability is denoted by p. A given TCR will only interact productively
with a small subset of the NA self-peptides. This subset is referred to as the stim-
ulatory subset of the given TCR (or clonotype) and the number of self-peptides
it contains is denoted by Na, with 1 ≤ Na ≤ NA. For a T-cell to receive a
survival signal, it may be necessary for the APP to present more than one self-
peptide from the stimulatory subset (of the given clonotype or TCR). Hence we
introduce the stimulation threshold, s, which is the number of self-peptides from
the stimulatory subset that need to be presented on the APP for the T-cell to re-
ceive a survival signal (note that 1 ≤ s ≤ Na). The number of distinct APPs that
present s self-peptides from the stimulatory subset is
(
Na
s
)(
NA−Na
NAPP−s
)
. For an APP
to provide a survival signal to T-cells of this clonotype it must present at least s
of the Na self-peptides from the stimulatory subset, so the total number of APPs
providing a survival signal is
∑Na
z=s
(
Na
z
)(
NA−Na
NAPP−z
)
. The probability that a T-cell
of this clonotype receives a survival signal from a random APP is given by the
number of APPs that can provide a survival signal divided by the total number of
APPs. Thus
p =
Na∑
z=s
(
Na
z
)(
NA−Na
NAPP−z
)(
NA
NAPP
) .
Similar combinatoric arguments can be used to calculate the mean niche overlap
of a given clonotype.
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